HDAC9 and cancer: As we are only at the beginning of understanding the potential therapeutic use of HDAC inhibition strategies and their combination within complex rationales utilizing several epigenetic-cancer therapies, further studies are required to define how to best construct drug strategies targeting epigenetic players such as HDACs and bromodomain and extra-terminal domain (BET) protein family members.